Investors
Advancing a new standard of care for vaginal infections.
Cern Corporation is developing the Cern Device™ — a prescription medical treatment consisting of a device which is to be used with our proprietary gel, targeting those who may experience yeast and or bacterial GYN infections, including those that may be recurrent through a non-pharma, light-based mechanism. Cern has created the category of device-based vaginal health intervention.
Market Opportunity
A Significant Market
Cern’s proprietary photosensitizing gel is designed to support visible spectrum light activity, assist device insertion, and
help optimize treatment efficiency without disrupting the vaginal microbiome.
Recurrence rates remain persistently high. Drug-resistant strains are accelerating in clinical prevalence. Recurrent BV carries broader reproductive health implications including increased preterm birth risk. No FDA-cleared medical device currently addresses this indication through a non-drug mechanism. Cern is building the first true solution which addresses both yeast & bacterial GYN infection without the potential, negative aspects of systemic, antifungal, antibiotic, drug-based therapies.
Development Status
Structured development.
Clear pathway.
01
IRB-approved human clinical evaluation underway
02
Non-Significant Risk (NSR) classification
03
Anticipated Class II De Novo regulatory pathway
04
Multiple issued patents — strong IP, domestic & global
05
Scalable device architecture supporting platform expansion
Request investor materials.
Cern is currently engaging qualified investors to support continued clinical
development and regulatory advancement.
By submitting, you agree to be contacted by Cern Corporation regarding investment
opportunities.